Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
14.01. | Arcutis Biotherapeutics, Inc.: ZORYVE (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids | 289 | GlobeNewswire (Europe) | New subgroup analysis from STRATUM study shows that individuals with an inadequate response, contraindication, or intolerance to steroids were 3.5 times more likely to achieve IGA Success with ZORYVE... ► Artikel lesen | |
14.01. | Arcutis Biotherapeutics, Inc.: Majority of Individuals with Atopic Dermatitis Improved with Arcutis' Roflumilast Cream 0.15% According to New Data from Phase 3 Program | 309 | GlobeNewswire (Europe) | Individual patient response data highlight 91.5% of individuals treated with roflumilast cream had a measurable improvement in Eczema Area and Severity Index (EASI) in just 4 weeks85% achieved measurable... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
GAMESTOP | 3.321 |
EVOTEC | 2.657 |
TUI | 2.094 |
NEL | 1.334 |
BAYER | 1.161 |
PLUG POWER | 1.155 |
NVIDIA | 1.154 |
RHEINMETALL | 1.071 |
AMC ENTERTAINMENT | 1.041 |
DEUTSCHE BANK | 976 |
SIEMENS ENERGY | 945 |
RENK GROUP | 879 |
REDCARE PHARMACY | 732 |
COMMERZBANK | 731 |
HEIDELBERGER DRUCK | 706 |
ALIBABA | 692 |
VOLKSWAGEN | 680 |
E.ON | 621 |
BARRICK GOLD | 620 |
BYD | 597 |
RWE | 591 |
TESLA | 578 |
DEUTSCHE LUFTHANSA | 567 |
SIEMENS | 566 |
AIXTRON SE | 560 |